Healthcare
Convatec Group Plc(CNVVY)
Live Price
Offline$10.82
+0.46% today
1Y Change
-31.24%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $5.51B
- Revenue Growth
- +6.8%
- EPS Growth
- -5.9%
- Dividend Yield
- 2.6%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Convatec Group Plc (CNVVY) is a Healthcare stock with a market cap of $5.51B and listed on OTC. The stock last traded around $10.82 and down 31.2% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +6.8%, EPS growth of -5.9%, a dividend yield of 2.6%. What stands out right now is revenue +6.8%, EPS -5.9%, free cash flow +22.5% with operating margin 16.5% and ROIC 9.6%. The dividend matters to the case here, with a current yield around 2.6%. Valuation already assumes a fairly strong business story at P/E 31.5 and price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CNVVY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.8% vs +7.6% peer median
Operating Margin
Below sector median
+16.5% vs +19.4% peer median
P/E
Below sector median
31.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 24, 2026 with an EPS surprise of -3.2% and a revenue surprise of +0.5%.
The operating picture looks softer than before
Revenue is at +6.8% and EPS is at -5.9%, with operating margin around 16.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 4, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | -3.2% | +0.5% | -7.4% | -11.0% |
2025 Jul 29, 2025 | -35.1% | -6.3% | -7.7% | -4.7% |
2025 Feb 26, 2025 | -32.7% | +3.1% | -11.1% | -14.9% |
Benchmark Edge
CNVVY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNVVY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNVVY Max Drawdown
-35.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CNVVY and SPY.
Company Overview
Convatec Group Plc
OTC
Convatec Group Plc is a global medical products and technologies company specializing in the development and manufacture of pioneering wound care, ostomy care, continence, and critical care solutions. Its primary function is to enhance healthcare outcomes and improve patients' quality of life through innovative products. As a key player in the medical supply industry, Convatec impacts sectors such as healthcare, pharmaceuticals, and biotechnology, supplying essential products to hospitals, clinics, and homecare settings around the world. Founded in 1978 and headquartered in Reading, United Kingdom, Convatec's significant role in the global market is underscored by its commitment to advancing medical solutions and addressing the complex needs of patients and healthcare professionals alike.
- Leadership
- Mr. Jonathan Peter Mason
- Employees
- 10.9k
- Street Address
- 20 Eastbourne Terrace, 7th Floor Paddington
- Mailing
- London, W2 6LG
- Region
- London, United Kingdom
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 31.5
- EV/EBITDA
- 11.4
- Price/Sales
- 2.3
- Price/Book
- 3.6
Growth
- Revenue
- +6.8%
- EPS
- -5.9%
- Free Cash Flow
- +22.5%
Profitability
- Gross Margin
- 55.8%
- Operating Margin
- 16.5%
- Net Margin
- 7.2%
- ROE
- 10.5%
- ROIC
- 9.6%
Balance Sheet
- Debt/Equity
- 1.06
- Current Ratio
- 1.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.